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ABSTRACT
Modifications of the bacterial ribosome regulate the
function of the ribosome and modulate its suscep-
tibility to antibiotics. By modifying a highly con-
served adenosine A2503 in 23S rRNA, methylat-
ing enzyme Cfr confers resistance to a range of
ribosome-targeting antibiotics. The same adenosine
is also methylated by RlmN, an enzyme widely dis-
tributed among bacteria. While RlmN modifies C2,
Cfr modifies the C8 position of A2503. Shared nu-
cleotide substrate and phylogenetic relationship be-
tween RlmN and Cfr prompted us to investigate evo-
lutionary origin of antibiotic resistance in this en-
zyme family. Using directed evolution of RlmN un-
der antibiotic selection, we obtained RlmN variants
that mediate low-level resistance. Surprisingly, these
variants confer resistance not through the Cfr-like
C8 methylation, but via inhibition of the endogenous
RlmN C2 methylation of A2503. Detection of RlmN
inactivating mutations in clinical resistance isolates
suggests that the mechanism used by the in vitro
evolved variants is also relevant in a clinical setting.
Additionally, as indicated by a phylogenetic analy-
sis, it appears that Cfr did not diverge from the RlmN
family but from another distinct family of predicted
radical SAM methylating enzymes whose function re-
mains unknown.
INTRODUCTION
As a critical component of the ribosome, ribosomal RNA
(rRNA) plays a vital role in protein synthesis. In all living
organisms rRNA carries wide range of physiological post-
transcriptional modifications that facilitate both the assem-
bly and the activity of the ribosome. Methylation of nu-
cleotides, both at nucleobases and the 2′-hydroxyl of the ri-
bose, is the most common rRNA modification in bacteria.
Many of thesemodifications are located in the functional re-
gions of the ribosome, such as the peptidyl transferase cen-
ter (PTC) and decoding centers, as well as at the interface
of ribosomal subunits. Although no single rRNAmodifica-
tion is critical for the survival of the cell, the presence of
individual methylations confers advantages under certain
growth or stress conditions (1). As the bacterial ribosome
represents a major antibiotic target, methylation of rRNA
has emerged as one of the most clinically relevant mecha-
nisms of resistance to ribosome-targeting antibiotics (2,3).
In most instances, methylation of rRNA alters the drug-
binding site thus reducing the ability of drugs to inhibit
the ribosome’s translational activity. For example, mono-
or dimethylation of the 23S rRNAnucleotideA2058 (E. coli
numbering), located in the exit tunnel, by Ermmethyltrans-
ferases interferes with the binding of macrolides and strep-
togramin B antibiotics (4,5). Less commonly, absence of
methylation can also confer antibiotic resistance (2,3,6–8).
For instance, the lack of methylation at A1518 and A1519
of 23S rRNA by KsgA confers resistance to kasugamycin
(9).
Methylation of rRNA in bacteria is carried out by a num-
ber of methylating enzymes. Among them, enzymes that
modify the PTC of the ribosome, the site of peptide bond
formation, are particularly interesting, as these enzymes
contribute to the control of protein biosynthesis and can
also mediate resistance to antibiotics (8,10). RlmN and Cfr
are two related bacterial enzymes that, by methylating 23S
rRNA at an adenosine located in the PTC region (A2503),
contribute to the post-transcriptional modifications of this
important region of the ribosome. RlmNmethylates A2503
at the C2 carbon (m2A), a modification that is nearly ubiq-
uitous among bacterial species (11). While the role of this
modification is yet to be fully understood, it has been sug-
gested that it regulates interactions between the ribosome
and the nascent peptide (12,13). Additionally, deletion of
rlmN reduces the accuracy of protein synthesis, an effect
attributed to the loss of methylation at A2503 (14). While
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the effects of the RlmN-mediated modification on bacterial
phenotypes are yet to be fully characterized, lack of RlmN
in S. aureus leads to an increase in linezolid resistance and
provides a slight fitness advantage over the WT S. aureus
cells (15).
While Cfr shares a nucleotide substrate with RlmN, it
preferentially methylates the C8 position of A2503, lead-
ing to resistance to phenicols, lincosamides, oxazolidinones,
pleuromutilins, streptogramin A, 16-membered macrolides,
as well as aminocyclitol hygromycin A and nucleoside an-
tibiotic A201A (7,16,17). Interestingly, Cfr can also methy-
late the C2 position of A2503 both in vivo (inΔrlmN strain)
and in vitro (with an in vitro transcribed rRNA fragment),
thus forming a 2,8-dimethyl adenosine (m2m8A) (18,19).
In addition to sharing a common nucleotide substrate and
overlapping reaction specificity, RlmN and Cfr are both
members of the radical SAM methylsynthase family shar-
ing 34% sequence identity (E. coliRlmN versus Cfr isolated
from S. aureus, hereafter S. aureus Cfr), and are consid-
ered to employ the same catalytic mechanism (18,20–25).
These observations indicate common ancestry of the Cfr
and RlmN families.
Unlike RlmNs, currently identified Cfrs are distributed
among pathogenic species, with exception of three Cfr-like
enzymes from the Bacillales order (26). Previous phyloge-
netic analysis of RlmN and Cfr-like enzymes indicated that
Cfr-like enzymes form awell-defined cladewithin theRlmN
family (27,28). Additionally, it was suggested that cfr may
have evolved from an rlmN ancestor via gene duplication,
but the lineage along which the duplication occurred is still
unknown (27). In this study, we implemented directed evo-
lution to examine if Cfr-like activity could be evolved from
RlmN in response to antibiotic pressure. Upon selection
we identifiedRlmNmutants conferring low-level resistance,
but remarkably, rather than the expected enzymes with Cfr-
like properties, these RlmN variants were catalytically in-
active towards 23S rRNA. The mutations conferring re-
sistance were specific, and did not include nonsense muta-
tions. Interestingly, these evolved variants successfully com-
pete with the endogenous E. coli RlmN for the A2503 of
23S rRNA in vivo, and as a result diminish the C2 methy-
lation of 23S RNA. Our findings suggest that inhibition of
C2 A2503 methylation is beneficial in the presence of cer-
tain antibiotics as previously suggested for S. aureus (15).
Rapid rise and maintenance of these dominant negative
variants through multiple rounds of evolution suggest that
this resistance mechanism can easily appear among clinical
pathogens. Our results expand the list of resistance mecha-
nisms resulting from lack of natural rRNA modifications,
and are compatible with the possibility that Cfr may not
have diverged directly from an RlmN, but rather, from an
RlmN related ancestor whose primary methylation target
is not A2503.
MATERIALS AND METHODS
Phylogenetic analysis
Seventy species from the Firmicutes phylum, with the
emphasis on the genus with higher coverage (i.e. Bacil-
lus and Staphylococcus) and Clostridium, were selected
from the Joint Genome Institute – Integrated Microbial
Genomes/Expert Review (IMG-er/JGI) database. From
this subgroup, RlmN and Cfr sequences were retrieved by
BLASTusing theRlmN sequence fromB. subtilis (hereafter
Bsub RlmN) as query. The E-value was set to 1e-5 to al-
low for the selection of sequences that share low identity
to the query. The sequences were aligned using MUSCLE
(29). The phylogenetic reconstruction was done in PhyML
(30), using the automatic model selection and selecting by
the Akaike Information Criteria.
Plasmids and strains used for the transformation, expression,
antibiotic susceptibility and methylation analysis
E. coli ER2267 was used in directed evolution experiments.
E. coli BL21(DE3) was used for overexpression of the His6-
tagged variants from either pET21a or pET15b vectors.
E.coli BW25113 and BW25113/rlmN strains were used
in antibiotic susceptibility tests and in in vivo methylation
assays. BW25113/rlmN strain, where the rlmN was re-
placed with the kanamycin resistance cassette, was a gener-
ous gift from Dr Alexander Mankin, University of Illinois
at Chicago, USA (31). The pZA vector was used in directed
evolution experiments, antibiotic susceptibility and in vivo
methylation analysis (32).
Library construction and selection
Random mutagenesis was performed by polymerase
chain reaction (PCR) using an error-prone polymerase
(GeneMorph Mutazyme, Stratagene). Wild-type (WT)
Bsub RlmN, or the pool of Bsub RlmN genes from the
previous round, was used as a template with primers
that flank the enzyme’s open reading frame. The protocol
was optimized to 1–3 mutations per gene. The mutated
Bsub RlmN genes were recloned into the pZA vector and
transformed into E.coli ER2267. Selection for the evolved
variants was performed on the LB agar plates containing
different concentrations of tiamulin (Wako Chemicals
USA). Additionally, each plate contained ampicillin (100
g/ml) and anhydrotetracycline (AHT; Sigma-Aldrich;
20 ng/ml). For each round of selection, the total transfor-
mation (1 ml) was divided into three aliquots and plated
onto LB agar plates containing varying concentrations of
tiamulin. The tiamulin concentration was increased in 25
g/ml increments. For example, in the first round of evolu-
tion the transformation was plated on the 75, 100 and 125
g/ml tiamulin plates, in the last round we selected on 150,
175 and 200 g/ml tiamulin plates. Two microliters were
plated on tiamulin deficient plates in order to determine
transformation efficiency. Cells were grown at 37◦C for up
to 48 h. Between the first and second rounds of evolution
(mutation and selection) we included an additional cycle
of selection with no mutagenesis (transformation, selection
and plasmid extraction). At the end of each round, 6–10
randomly chosen clones, from each tiamulin concentration,
were isolated and sequenced.
Antibiotic susceptibility tests
Drug susceptibility was tested on the LB agar plates. Each
plate contained 100 g/ml of ampicillin for the selection
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of the plasmid and 20 ng/ml of AHT for the expression of
the enzymes. Plates also contained 50 g/ml of kanamycin
when antibiotic susceptibility was tested in the E. coli
rlmN strain. In a standard experiment, 2 ml of LB media
containing appropriate antibiotics were inoculated from a
fresh colony. Cultures were grown at 37◦C for∼3 h, at which
point OD600 was measured and the cultures were diluted to
108, 106 and 104 cells. A 3 l aliquot of each dilution was
spotted on the agar plates. Plates were incubated at 37◦C for
24–48 h. MICs of the antibiotics were determined by the
broth microdilution assay following ref (33). LB medium
was inoculatedwith single colonies harboring plasmidswith
WT Bsub RlmN or Bsub RlmN variant genes and incu-
bated at 37◦C for 4–5 h. The cultures were diluted to OD600
= 0.001 and 50 l of diluted culture was mixed with 50
l of antibiotic solution prepared in LB medium. Expres-
sion of enzymes was induced by addition of AHT to the an-
tibiotics solution (final concentration 20 ng/ml). The tested
concentration ranges were: for tiamulin, 250 to 1800 g/ml
(in 50 g/ml steps from 250 to 600 g/ml followed by 200
g/ml steps to 1800 g/ml); for clindamycin (TCI Amer-
ica), 50 to 1200 g/ml (in 50 g/ml steps from 50 to 400
g/ml followed by 100 g/ml steps to 800 g/ml and 200
g/ml steps to 1200 g/ml); for chloramphenicol (Acros),
0.5 to 32 g/ml (in 2-fold concentration steps); for virgini-
amycin M1 (Cayman Chemical), 100 to 1200 g/ml (in 50
to 100 g/ml concentration steps to 600 g/ml followed by
200 g/ml steps to 1200 g/ml); for trimethoprim (Sigma-
Aldrich), 0.125 to 2 g/ml (in 2-fold concentration steps).
The MIC values were determined after an overnight incu-
bation (16–18 h) at 37◦C by measuring the optical density
at 600 nm with a microtiter plate reader (SpectraMax M5,
Molecular Devices). The MIC was defined as the drug con-
centration with no visible growth. Each value is a replicate
of at least three independent experiments.
Expression and purification of Bsub RlmN evolved variants
WT Bsub RlmN and evolved variants were expressed, pu-
rified and reconstituted for their iron-sulfur clusters us-
ing modified versions of previously published protocols
(18,34,35). Briefly, enzymes were overexpressed and puri-
fied by Talon chromatography (Clontech). After chemical
reconstitution of the iron-sulfur cluster, proteins were fur-
ther purified by FPLC either on a Superdex 200 10/30 col-
umn or on a HiLoad 26/60 Superdex 75 Prep grade column
(GE Healthcare Life Sciences) using 10 mM HEPES (pH
7.5) buffer containing 500 mM NaCl, 10% glycerol and 5
mMDTT. The fractions containing protein were combined
and concentrated before being stored at −80◦C.
Preparation of truncated rRNA substrates and tRNAs for the
in vitro methylation assay
E. coli 23S rRNA fragments 2447–2625 and 2018–
2625 used in in vitro methylation assay were generated
by in vitro transcription following previously published
methods (18,35). pGOV4 vectors containing genes for
tRNAAspGUC, tRNAGlnUUG, tRNAGluUUC, tRNAHisGUG
and tRNAGlyCCC were purchased from Gene Oracle. T7
promotor sequence was inserted in front of these gene, while
BamHI sequence was inserted at the end of the gene. Prior
to the in vitro transcription reaction, vector was linearized
with BamHI (New England Biolabs) at 37◦C for 14 h. Lin-
earized vector was purified using Qiagen PCR cleanup kit
prior to in vitro transcription reaction following the same
procedure as for the rRNA fragments.
In vitro methylation assay
Methylation activity of the evolved variants was assessed by
monitoring the radioactivity incorporation into RNA. Re-
actions were performed in 100 l volumes under the follow-
ing conditions: 100 mM HEPES pH 8.0, 100 mM KCl, 10
mMMgCl2, 2 mM DTT, 20 M Flavodoxin, 2 M Flavo-
doxin reductase, 4 M RNA and 0.14 Ci [14C-methyl]-
SAM (58 mCi/mmoL) and 1.3–14 M enzyme. Reactions
were initiated by addition of NADPH (final concentration
1 mM), and were allowed to proceed at 37◦C for 1–1.5
h. The RNA was recovered from the reaction mixture us-
ing the RNA Clean & Concentrator kit (Zymo Research)
and added to the vials containing Ultima Gold scintillation
fluid. The amount of radioactivity incorporated in the prod-
uct was measured using Beckman–Coulter LS6500 multi-
purpose scintillation counter (Fullerton, CA, USA). Each
value represents the average of at least triplicate (for reac-
tions with rRNA) or duplicate (for reactions with tRNA)
measurements, with one standard deviation (SD) indicated.
HPLC separation and identification of methylated
adenosines
The methylated rRNA from WT Bsub RlmN assay mix-
tures was purified using the RNAClean &Concentrator kit
(ZymoResearch). Subsequently, the purified rRNAwas en-
zymatically digested to mononucleosides using nuclease P1
(Sigma-Aldrich), snake venom phosphodiesterase (Sigma-
Aldrich) and antarctic phosphatase (New England Bio-
labs). The digested samples were separated on HPLC us-
ing Luna analytical C18 column (10 m, 4.6 mm × 250
mm) (Phenomenex, Torrance, CA, USA) and previously
published protocol (18). The mononucleosides and the syn-
thetic methyladenosines were detected by their UV absorp-
tion at 256 nm, while the 14C-labled mehyladenosines were
detected by a Packard radiomatic 515TR flow scintillation
analyzer (Perkin–Elmer).
Preparation of rRNA fragments and MALDI analysis
For isolation of total RNA, E. coli BW25113 or
BW25113/rlmN strains harboring appropriate pZA
plasmid were grown in LB medium at 37◦C in the presence
of inducer, AHT (final concentration 20 ng/ml) to an
OD600 of 0.6–0.8. The total RNA was purified using
RNeasy Midi Kit (Qiagen) following manufacturer’s
recommendations. The 41-mer fragment encompassing
A2503 (C2480–C2520), was isolated using an established
complementary oligodeoxynucleotide procedure (35,36).
A total of 25–30 pmol of isolated RNA fragment was
mixed with 0.5 volumes of 0.5 M 3-hydroxypicolinic acid
(3-HPA; Sigma-Aldrich) and 500 U of RNase T1 (US
Biological) and left to digest at 37◦C for 3 h. To linearize
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cyclic phosphates that result from the RNase T1 digestion,
0.25 volumes of 0.5 M HCl were added and the mixture
was left at room temperature for 30 min. The samples were
lyophilized, and then re-dissolved in water. One microliter
of the sample was spotted onto the target plate and mixed
with 1 l of 0.5 M 3-HPA. Spectra were recorded in
a reflector and positive ion mode either on a Voyager
Elite STR MALDI-TOF mass spectrometer (Applied
Biosystems/Life Technologies) or AXIMA Performance
MALDI TOF/TOFMass Spectrometer (Shimadzu).
RESULTS
To date, all known Cfr enzymes capable of C8 methylation
at A2503 and associated with antibiotic resistance belong
to the Firmicutes phylum. As it has been previously spec-
ulated that Cfr evolved from RlmN (27,28), we hypothe-
sized that Cfr-like functionality could have evolved from
an RlmN belonging to this bacterial phylum. To test this
hypothesis, we examined the RlmN of the model organ-
ism for gram-positive Firmicutes species, namely B. subtilis
(Bsub RlmN).
Bsub RlmN shares slightly higher sequence identity to
known Cfrs than E. coli RlmN (Ecoli RlmN; 39% and
34%, respectively). A previous study showed that in vivo
Bsub RlmNmethylates C2 position of A2503 in 23S rRNA
from E. coli (28), which we confirmed both in vivo and
in vitro (described below). Additionally, as observed with
other RlmNs, no C8 methylation of A2503 was detected
with Bsub RlmN, even at high enzyme to substrate ratio
(e.g. 7:1). Promiscuous activities are considered the rawma-
terial for evolutionary innovations (37). Nonetheless, we
endeavored to examine whether, under antibiotic selection
pressure, Cfr-like functionality could evolve.
Evolved Bsub RlmN variants mediate increased antibiotic re-
sistance
Using error-prone PCR, we introduced random 1–3 muta-
tions per bsub rlmN gene cloned into a medium copy num-
ber plasmid, pZA (32). A library comprising of ∼107 WT
E. coli transformants was subjected to selection under in-
creasing amounts of tiamulin, a PTC antibiotic to which
Cfr confers resistance (Supplementary Figure S1). Subse-
quently, the bsub rlmN genes were recovered from all surviv-
ing colonies and were subjected to amplification with fur-
ther error-prone mutagenesis and selection. The selection
pressure was gradually strengthened by increasing the con-
centration of the antibiotic from 75 to 125 g/ml and up
to 200 g/ml. In total, three rounds of random mutagene-
sis and selection were performed to gradually increase the
ability of E. coli to survive in the presence of tiamulin.
As early as the first round of evolution we noticed dif-
ferent colony sizes, which were not observed in a con-
trol plate containing solely E. coli transformants with WT
Bsub RlmN, indicating that certain RlmN mutations were
advantageous to cell survival in the presence of tiamulin.
Accordingly, the surviving clones did not carry the wild-
type RlmN gene and were enriched in mutations in cer-
tain positions (e.g. S168 and G201). By the third round,
the sequences of randomly chosen variants indicated con-
vergence, with a few specific mutations dominating the sur-
viving pool (Supplementary Table S1). Most of the prevail-
ing amino acid substitutions were located far from the ac-
tive site (>12 A˚; Figure 1A). One of the few exceptions was
the A348T mutation (Figure 1A), located in the highly con-
served C-terminal region of RlmN and a part of the ac-
tive site upon substrate binding (38). More than 50% of the
tiamulin selected clones contained S168C and G201D, two
mutations that usually appeared together (Supplementary
Tables S1 and S2). Q89R was also one of the more preva-
lent mutations after the first round of evolution, usually
occurring together with G201D (Supplementary Table S1).
This mutation was not observed in the second round, yet it
reemerged in the third round. Importantly, nonsense muta-
tions (frame shifts and stop codons) were not observed in
the selected variants.
We consequently focused on the in vivo and in vitro
functional characterization of the three evolved variants
that represented the most prevalent mutational combina-
tions present in the tiamulin resistant variants (dubbed
Bsub RlmN variants B, F and K; Figure 1B). An antibi-
otic susceptibility test clearly indicated that E. coli cells ex-
pressing the Bsub RlmN B, F and K variants grew bet-
ter in the presence of tiamulin than cells carrying the WT
Bsub RlmNor an empty plasmid (Figure 2A). The selective
survival of cells expressing evolved variants was observed
at tiamulin concentrations up to 200 g/ml (Figure 2A).
Tiamulin resistance was also dose-dependent with respect
to the enzymes’ expression levels, as determined by vary-
ing concentration of the pZA plasmid inducer, AHT (Sup-
plementary Figure S2). Even though E. coli cells express-
ing the evolved Bsub RlmN variants show growth advan-
tage in comparison to cells carrying theWT Bsub RlmN or
an empty plasmid, their minimum inhibitory concentration
(MIC) values are lower in comparison to cells expressing S.
aureusCfr (18,19) (Supplementary Figure S3 and Table S3).
We subsequently examined if these variants confer sur-
vival advantage in the presence of other PTC antibiotics
known to be affected by Cfr-mediated rRNA methylation.
Three additional clinically important PTC antibiotics were
tested: a lincosamide antibiotic, clindamycin; a phenicol,
chloramphenicol; and a streptograminA, virginiamycinM1
(Supplementary Figure S1). While preferential growth of
strains expressing Bsub RlmN variants was observed in the
presence of virginiamycinM1 (VIRM1; Figure 2B and Sup-
plementary Table S3), no growth advantage was observed
in the presence of clindamycin and chloramphenicol (Fig-
ure 2B). Additionally, MIC values obtained by broth mi-
crodilution method suggest the same trend (Supplemen-
tary Table S3). MIC values of tiamulin for cells expressing
evolved variants are ∼1.5-fold higher than those express-
ing WT Bsub RlmN. For virginiamycin M1, this effect is
more subtle (400 g/ml for variants and 300 g/ml forWT
Bsub RlmN) yet reproducible. No difference inMIC values
was observed for clindamycin and chloramphenicol, which
is in accord with the results obtained from the antibiotic
susceptibility test on agar plates (Figure 2B).
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B S168C, G201D
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Figure 1. Evolved variants of Bsub RlmN contain specific mutations distal from the active site. (A) A homology model of the structure of Bsub RlmN
was generated by I-TASSER. Shown in sticks are the iron-sulfur center (gold) and the SAM cofactor (light blue) borrowed from the aligned template
structure (PDB 3RFA). The most dominant mutations present in the evolved variants are shown as red sticks. Among the mutated residues present in the
Bsub RlmN variants studied herein, only A348, part of the C-terminal region that undergoes conformational change upon substrate binding, is a part of
the active site, while other residues are located>12 A˚ from SAM’s methyl group (38). (B) Mutations present in the 3 evolved Bsub RlmN variants analyzed
in this study.
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Figure 2. Antibiotic susceptibility of E.coli transformed with plasmid-encoded Bsub RlmN variants. (A) Dose-dependent antibiotic susceptibility test
towards tiamulin. (B) Antibiotic susceptibility test toward several PTC-targeting antibiotics. All plates contained ampicillin (the plasmid resistance marker)
and AHT to induce the expression of the Bsub RlmN variants. Cells were plated at three densities, and plates were recorded after 24 h. Abbreviations: Neg
= empty pZA; WT = pZA WT Bsub RlmN; B = pZA BsubB; F = pZA BsubF; K = pZA BsubK; TIA = tiamulin; VIR M1 = virginiamycin M1; CLI
= clindamycin; CHL = chloramphenicol.
Evaluation of in vitro activity of Bsub RlmN evolved variants
We next evaluated the in vitro activity of the evolved
Bsub RlmN variants. Our hypothesis was that, similar to
Cfr, these enzymes would methylate A2503 at the C8 po-
sition, given their ability to confer an increase in an-
tibiotic resistance. All three selected variants (Figure 1B)
were successfully expressed and purified, and their cat-
alytic iron–sulfur clusters were readily reconstituted. Using
an established in vitro assay (35), we investigated the ac-
tivities of the evolved enzyme variants by monitoring the
accumulation of radioactivity from S-adenosyl- l-[methyl-
14C]methionine ([14C-methyl]-SAM) in a fragment of 23S
rRNA encompassing A2503 (Figure 3). While, as expected,
WT Bsub RlmN successfully methylated C2 position of
A2503 in 23S rRNA in vitro (Figure 3 and Supplementary
Figure S4), none of the evolved variants couldmethylate the
rRNA fragments (Figure 3). We then examined if these mu-
tations might have changed the substrate specificity of the
0
5000
10 000
15 000
BsubB
BsubF
BsubK
BsubWT
no NADPH
rRNA(2447–2625) rRNA(2018–2625)
D
P
M
Figure 3. Methylation of 23S rRNA by WT Bsub RlmN and its evolved
variants. In vitro measurement of the methylation activity of Bsub RlmN
variants toward fragments of E. coli 23S rRNA. The assay monitored in-
corporation of the radioactivity from [14C-methyl]-SAM (24.9 M) into
the rRNA fragment (4 M), after 1 h incubation with 14 M enzyme at
37◦C. Error bars (n ≥ 3), S.D.
8902 Nucleic Acids Research, 2016, Vol. 44, No. 18
control
Neg WT B F K
108
106
104
Neg WT B F K Neg WT B F K
Neg WT B F K Neg WT B F K Neg WT B F K
108
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104
CLI – 100 μg/ml CHL – 2.5 μg/ml STR – 4 μg/ml
TIA – 200 μg/ml VIR M  – 100 μg/ml1
Figure 4. Antibiotic susceptibility of E.coliΔrlmN strain expressing
plasmid-encoded wild-type and evolved Bsub RlmN variants. All plates
contained ampicillin (the plasmid selection marker), kanamycin for selec-
tion of the rlmN strain and AHT to induce the expression of the RlmN
variants. Cells were plated at three densities, and plates were recorded after
24 h. Abbreviations: Neg = empty pZA; WT = pZA WT Bsub RlmN; B
= pZA BsubB; F= pZA BsubF; K= pZA BsubK; TIA= tiamulin; VIR
M1 = virginiamycin M1; CLI = clindamycin; CHL = chloramphenicol;
STR = streptomycin.
Bsub RlmN evolved variants, based on the report that E.
coliRlmN can also methylate a subset of tRNAs (14). An in
vitro activity assay showed that neither theWTBsub RlmN
(Supplementary Figure S5A) nor any of the evolved vari-
ants can methylate the tested tRNAs, which is in accord
with no identified tRNA A37 methylation in B. subtilis tR-
NAs (39) (Supplementary Figure S5B).
These findings suggest that the evolved variants not only
lacked Cfr-like reactivity, but have also lost the RlmN-like
activity, implying that inactivation ofRlmN is beneficial un-
der tiamulin selection pressure. Interestingly, the inactiva-
tion of Bsub RlmN was not achieved through random in-
sertions of stop codons or frame shifts or via other severely
deleterious mutations that typically cause misfolding or ag-
gregation. Such mutations are frequent amongst the reper-
toire of random mutations. Rather full length, soluble and
folded, albeit inactive variants of Bsub RlmNwere selected
for.
Lack of methylation at A2503 decreases antibiotic suscepti-
bility
Several previous studies attempted to examine if the lack of
RlmN is beneficial under antibiotic pressure (11,15). Dele-
tion of rlmN in E. coli leads to a slight increase in sus-
ceptibility toward several PTC antibiotics (11). In contrast,
inactivation of rlmN in S. aureus leads to an increase in
linezolid resistance. Furthermore, in co-growth experiments
under linezolid pressure, S. aureus lacking functional RlmN
outcompetes the strain with an active RlmN (15). To eval-
uate the link between RlmN and low-level resistance to
PTC antibiotics in E. coli, and to determine the effect of
the evolved variants on antibiotic susceptibility, we exam-
ined antibiotic sensitivity of the rlmN knockout strain (E.
coli BW25113/rlmN) expressing an empty plasmid, WT
Bsub RlmN or the evolved variants (Figure 4, Supplemen-
tary Figure S6 and Supplementary Table S3). Our results
show that RlmN knockout cells that carry an empty pZA
plasmid, and thus are not methylated at A2503, survive
equally well as knockout cells expressing evolved variants
in the presence of tiamulin, clindamycin and virginiamycin
M1, three antibiotics that target PTC. The only exception
are cells expressing the BsubB variant in the presence of vir-
giniamycinM1 where it is not clear if expression of this par-
ticular variant is advantageous. In contrast, cells expressing
the WT Bsub RlmN and thus have their rRNA methylated
at the C2 position of A2503, are more susceptible to tia-
mulin and slightly more to clindamycin, while this suscep-
tibility is not observed for chloramphenicol, another PTC-
targeting antibiotic (Figure 4). To further explore these ef-
fects we measured the MIC values by the broth microdi-
lution method. MICs of tiamulin and virginiamycin M1
against RlmN knockout cells that carry an empty plasmid,
or are expressing evolved variants, are higher thanMIC val-
ues for these antibiotics whenWT Bsub RlmN is expressed
in the same strain (Supplementary Table S3). However, the
MIC values of clindamycin and chloramphenicol for E. coli
BW25113/rlmN cells expressing WT Bsub RlmN are not
significantly different from MIC values obtained for these
cells when expressing the evolved variants or carrying an
empty plasmid. No difference in the cell growth was ob-
served for streptomycin, an aminoglycoside that targets 30S
subunit (Figure 4). Similarly, no difference in the MIC val-
ues of trimethoprim, an antibiotic that interferes with folate
metabolism, was observed (Supplementary Table S3).
Overall, the comparison between the cell survival of E.
coli ΔrlmN expressing the WT Bsub RlmN and those con-
taining the empty plasmid indicates that the lack of C2
methylation at A2503 is beneficial in the presence of a sub-
set of PTC antibiotics. Furthermore, the similarity in an-
tibiotics tolerance between ΔrlmN cells carrying the empty
plasmid and WT cells expressing the evolved variants sug-
gest that although the evolved variants do not modify
A2503 of 23S rRNA as described above, they may act as
dominant negative proteins, potentially via binding of the
rRNA substrate, thus preventing methylation of A2503 by
the endogenous RlmN.
Bsub RlmN evolved variants act as dominant negative en-
zymes
To elucidate if the evolved Bsub RlmN variants interfere
with the E. coli RlmN-catalyzed methylation at C2 posi-
tion of A2503, we analyzed the extent of methylation of
A2503 by matrix-assisted laser desorption ionization-time
of flight (MALDI-TOF) mass spectrometry. Specifically,
using an oligonucleotide protection assay, a fragment of 23S
rRNA (2480–2520) that includes A2503 was isolated, di-
gested to ≥ 3-nt long oligonucleotide fragments and ana-
lyzed by MALDI-TOF mass spectrometry (Figure 5). Uti-
lizing this approach, we examined RNA fragments isolated
from the WT E. coli strain (that contains an endogenous
copy of RlmN; Figure 5A), and from WT E. coli that also
expresses BsubB variant (Figure 5B). We focused on the
BsubB variant since this variant best represented the most
prevalent mutations found in the tiamulin resistant clones.
Analysis of samples obtained from the strain expressing
only the endogenous copy of RlmN indicated that the peak
atm/z 1013.20, corresponding to m2A2503, is more promi-
nent than the peak at m/z 999.14 that corresponds to un-
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Figure 5. Reduction of in vivomethylation at A2503 upon expression of BsubB supports the dominant negative function of the evolved variants. MALDI-
TOF mass spectrum of the C2480–C2520 fragment of E. coli 23S rRNA isolated from the WT E. coli BW25113 strain carrying an (A) empty plasmid,
or expressing (B) evolved BsubB variant. RNA was digested by RNase T1 and analyzed by MALDI-TOF. Comparison between the insets shows a sig-
nificant reduction in the amount of methylated 2503-m2AG-2505 fragment at m/z 1013.16 when the BsubB variant is overexpressed. (C) A list of the
expected RNase T1 digestion fragments based on the rRNA sequence with presently known nucleotide modifications. Cm is methylated cytosine, m2A is
2-methyladenosine, and  indicates pseudouridine.
methylated A2503. This finding indicates that A2503 is pre-
dominately methylated by the endogenous RlmN in WT E.
coli cells. However, the ratio between the peak atm/z 999.34
and the peak at m/z 1013.18 changes from approximately
1:4 inWTE. coli cells to 9:1 in cells where the evolvedBsubB
variant is expressed (Figure 5B). These findings support the
hypothesis that the evolved variant BsubB acts as a dom-
inant negative protein, preventing methylation by the en-
dogenous RlmN.
To further corroborate that the evolved Bsub RlmN vari-
ants do not methylate A2503, we examined the methylation
status of A2503 in 23S rRNA isolated from rlmN cells
expressing either WT Bsub RlmN, BsubB evolved vari-
ant or S. aureus Cfr. While mono-methylation of A2503
(peak at m/z 1013.32) was observed in cells expressing WT
Bsub RlmN, clearly indicating that 23S rRNA of E. coli is
a substrate for this enzyme, no methylation was observed in
cells expressing the evolved BsubB variant (Supplementary
Figure S7). These findings confirm that the evolved vari-
ants lack methylation activity toward the 23S rRNA. Both
mono- and dimethylation of A2503 (peaks at m/z 1013.34
and 1027.37, respectively) were observed in cells expressing
S. aureus Cfr, recapitulating previously published in vitro
data (18) (Supplementary Figure S7D).
Phylogenetic analysis of the Firmicutes RlmN and Cfr fami-
lies
Our findings indicate that directed evolution of Bsub RlmN
under antibiotic pressure did not readily yield enzymes with
Cfr-like activities. Instead, upon selection for higher resis-
tance to PTC antibiotics, rather than evolving toward C8
methylation of A2503, Bsub RlmN evolved to confer resis-
tance by obstructing C2 methylation of A2503. In addition,
neither we nor others could detect promiscuous levels of
C8 methylation of A2503 in RlmNs, neither in the broadly
studied Ecoli RlmN, nor in the Bsub RlmN examined here
(18,28).We thus reexamined theRlmN-Cfr phylogeny in or-
der to reevaluate the hypothesis that Cfr may have evolved
from RlmN under selection for survival in the presence of
high levels of PTC binding antibiotics.
Previous phylogenetic analyses indicated that known
RlmNs and Cfrs comprise two distinct clades (27,28). Ad-
ditionally, a separate clade containing Cfr-like sequences
that are particularly abundant in the Clostridia class was
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detected (28). To further examine the relationships between
these three families, we performed a phylogenetic analysis
of the Cfr-like and RlmN-like orthologous from selected
Firmicutes species, with an emphasis on the Clostridia
class. Sequences were retrieved from the Integrated Mi-
crobial Genomes – Joint Genome Institute (IMG/JGI)
database using BLAST, and aligned prior to the generation
of the phylogenetic tree by maximum likelihood method
(PhylML) (Figure 6). Overall, our tree corroborated previ-
ously reported trees where the Cfr sequences from clinical
and veterinary samples appear as a separate subgroup that
branches out of theRlmN family (27,28).However, the clos-
est clade to known Cfr enzymes are not RlmNs but rather
a group of clostridial genes currently annotated as Cfr-like
proteins (Figure 6, Supplementary Figure S8).
Previous examination of one of these genes, a Cfr-like
gene from C. sporogenes, indicated that this enzyme is un-
able to methylate rRNA (28). We have examined another
gene from this clade, a Cfr-like gene fromC. phytofermentas
–ClCp, and also could not observe methylation of A2503 in
23S rRNA either in vivo or in vitro (Supplementary Figure
S9). Furthermore, our attempts to evolve the Cfr-like func-
tionality in ClCp, namely C8 methylation of A2503, were
also unsuccessful. Several libraries derived from WT ClCp
were constructed and selected as described for Bsub RlmN,
yet colonies expressing ClCp variants that confer higher re-
sistance to tiamulin compared to the cells expressing WT
ClCp were not observed. In addition, we did not observe
enrichment of specific mutations in sequenced variants or
the dominant negative variants, as it was the case with
Bsub RlmN. We cannot completely exclude the possibility
that ClCp has RlmN/Cfr-like activity, as this protein may
be able to methylate the Clostridium 23S rRNA and not the
E. coli 23S rRNA. However, this seems unlikely given the
high sequence identity between the 23S rRNA of E. coli
and C. phytofermentas (80%). Additionally, for one of the
knownCfrs from clinical isolates of pathogenPeptoclostrid-
ium difficile, C8 methylation of A2503 was successfully re-
capitulated in E. coli (40). It therefore appears that Cfr-like
genes comprise a distinct family of enzymes that notice-
ably differ in function from both RlmN and Cfr and whose
methylation target(s), if any, remain unknown.
DISCUSSION
In the present study, we investigated how a specific post-
transcriptional modification in 23S rRNA affects suscepti-
bility to PTC-targeting antibiotics. Specifically, we focused
on the methylation of A2503 in 23S rRNA, a nucleotide lo-
cated in the PTC region of the ribosome. This base is subject
to methylation by two evolutionary related enzymes, RlmN
that catalyzes methylation at the C2 position of A2503, and
Cfr that is responsible for the C8 methylation of A2503.
While it has been shown that the methylation at C8 po-
sition leads to multi-antibiotic resistance, the effect of C2
methylation by RlmN on antibiotic resistance remains un-
clear. Further, the evolutionary origins of Cfr remain un-
known. RlmN is widely spread, whereas Cfr is sporadi-
cally observed in high resistance strains and only in spe-
cific bacterial clades. The most plausible hypothesis is thus
that Cfr evolved from an RlmN (27,28), but this hypothesis
has not been validated. The results of our laboratory evo-
lution experiment indicate that antibiotic pressure leads to
evolution of catalytically inactive variants of RlmN. Rather
than methylating the C8 position of A2503, these variants
act as dominant negative proteins to prevent C2 methyla-
tion of A2503 by the endogenous E. coli RlmN, providing
an immediate selective advantage under tiamulin pressure.
These observations highlight the critical role of methylation
of A2503 in regulating the response to antibiotics as it ap-
pears that both lack of the methylation at C2 position, and
C8 methylation by acquisition of Cfr, lead to the antibiotic
resistance (7,16).
The evolved variants likely exert their dominant negative
function by competing with the Ecoli RlmN for 23S rRNA.
Since RlmN only modifies the free 23S rRNA, and not the
large ribosomal subunit nor fully assembled ribosome (18),
methylationmust occur during the narrow time frame when
23S rRNA is available prior to its incorporation into the
large ribosomal subunit. The evolved variants likely inter-
fere with this process by blocking the access of Ecoli RlmN
to 23S rRNA. The effectiveness of each of the variants in
preventing the methylation likely depends both on their
affinity for 23S rRNA and their stability and thereby on
their cellular concentrations. Once incorporated into the
large subunit, lack of methylation cannot be corrected by
endogenous RlmN as A2503 in 23S rRNA is no longer ac-
cessible for methylation. The requirement for the competi-
tion with Ecoli RlmN during the selection may also ratio-
nalize the observation that our evolution experiments, per-
formed in theWT E. coli, yielded stable, full length, yet cat-
alytically inactive proteins. While nonsense and frameshift
mutations would also yield catalytically inactive proteins,
they would be unlikely to compete with the WT RlmN for
binding to the substrate.
Many rRNA methylating enzymes function as antibiotic
resistance determinants by modifying various nucleotides
(Supplementary Table S4). Only in a few instances, however,
was the absence of rRNA methylation found to increase
antibiotic resistance (41–44). Consistent with the previous
study on S. aureus RlmN (15), our findings indicate that
the lack of RlmN-mediated modification of A2503 in 23S
rRNA similarly yields decreased susceptibility to tiamulin
and virginiamycin M1. How lack of methylation at A2503
leads to an antibiotic resistance phenotype is not com-
pletely clear. From the available bacterial ribosome crys-
tal structures, it is evident that A2503 belongs to a region
that defines the binding pocket for the PTC-targeting an-
tibiotics. It is therefore possible that the lack of methyla-
tion by RlmN changes the local structure of PTC, subse-
quently affecting binding of some PTC-targeting antibiotics
but not others. Furthermore, our observations that sub-
strates of Ecoli RlmN, 23S rRNA and several tRNAs are
not modified by the evolved variants strongly supports the
notion that the evolved proteins are not catalytically active.
We cannot, however, exclude the possibility that the evolved
variants might be catalytically active toward currently un-
known targets, although it is unclear how modification of
other possible RNAs might contribute to the resistance to-
ward PTC-targeting antibiotics.
From the perspective of protein evolution, our findings
do not support the prevailing hypothesis that Cfr-like func-
Nucleic Acids Research, 2016, Vol. 44, No. 18 8905
0.7
B. clausii
B. brevis
C. hathewayi
Staphylococcus (clade I)
C. sporogenes
C. celerecrescens
P. st GY412MC10
C. difficile
C. acidurici
Geobacillus
B. methylotrophicus
C. mangenotii
S. aureus
B. clausii
C. saccharolyticum
Paenibacillus (clade II)
Bacillus (B. subtilis)
Enterococcus
B. brevis
C. saccharoperbutylacetonicum
B. coagulans
P. difficile
Listeria
Staphylococcus (clade II)
Clostridium
C. clostridiiforme
B. amyloliquefaciens
Paenibacillus (clade I)
C. phytofermentans
1
1
1
1
0.99
1
1
1
0.91
1
1
1
1
1
1
1
1
0.67
0
1
1
0
0.75
1
1
1
1
0.77
1
RlmN
Cfr
Cfr -like 
* 
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tion diverged from RlmN, and that this divergence pro-
ceeded via a gradual change in the methylation specificity,
namely, from exclusive methylation of C2 of A2503 in
RlmN, to C8-A2503 (with residual C2-A2503 methylation
as observed in Cfrs). Rather, our observations indicate that
despite their sequence homology, and the overlap in sub-
strate specificity, RlmNs and Cfrs are only distantly related.
Similar conclusions were also reached in a recent study by
Ntokou et al. who explored the functional linkage between
Cfr and RlmN by swapping different amino acid segments
in their respective active sites (45). A distant evolutionary
connection between RlmNs and Cfrs is also suggested from
the phylogenetic analysis since the closest family to Cfr does
not exhibit either RlmN or Cfr activity (Supplementary
Figure S9) (28). The functional divergence of the radical
SAMmethylsynthase family is also suggested from the phy-
logenetic analysis where we detected the presence of several
species with paraloguous RlmNs. Specifically, most Paeni-
bacillus species possess two or more putative RlmNs, and
a maximum of 4 paralogous RlmN/Cfr-like enzymes were
detected in P. durum (data not shown). Multiple paralogs
present an added difficulty in selection of a starting point
for directed evolution experiments.
Our findings also hold important clinical implications.
Loss-of-function mutations are far more frequent than
gain-of-function. The fact that loss-of-function mutations
arose rapidly in our directed evolution experiment and were
maintained through multiple rounds of evolution suggests
that similar mutations may be easily acquired in a clinic set-
ting. Such mutations may become more common with the
increased use of antibiotics. Interestingly, an amino acid in-
sertion into a highly conserved C-terminal region of RlmN
was observed in methicillin resistant Staphylococcus aureus
(MRSA) isolates from a patient with a persistent and recur-
rent infection that was resistant to oxazolidinone linezolid,
a PTC-targeting antibiotic (46). A causative relationship be-
tween this genetic alteration of rlmN and antibiotic suscep-
tibility was confirmed by introduction of the insertion mu-
tant into the parent strain which recapitulated linezolid re-
sistance. This insertion was subsequently shown to inacti-
vate RlmN, linking the loss of C2 methylation of A2503 to
the clinical linezolid low-level resistance (15). Mutations in
rlmN have also been reported in clinical isolates of linezolid-
resistant S. capitis, although their individual contributions
to antibiotic susceptibility are difficult to discern given the
presence of other alterations associated with linezolid resis-
tance (47). These observations indicate the importance of
monitoring RlmN mutation status along with other com-
monly monitored resistance mechanisms such as acquisi-
tion of cfr, mutations in domain V of 23S rRNA and mu-
tations in ribosomal proteins L3 and L4, in clinical isolates
of linezolid-resistant Staphylococci (7,48–53). Together, our
laboratory evolution experiments and the clinical observa-
tions illuminate a possibility that mutations that lead to a
loss of RlmN-mediated methylation of A2503 could readily
elicit resistance to antibiotics that target the PTC of the ri-
bosome. From the perspective of clinical use of PTC antibi-
otics, this is particularly worrisome since the lack of methy-
lation by RlmN has a minimal effect on the cell fitness (15),
and inactivatingmutations, according to our findings, easily
emerge after exposure to antibiotics.
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